Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Peter J. Arduini, a director at Bristol-Myers Squibb, acquired 596.711 deferred share units on December 31, 2024, convertible to common stock upon his departure as a director or at a previously specified date.

Summary

• Peter J. Arduini, a director of Bristol-Myers Squibb, acquired 596.711 deferred share units on December 31, 2024.
• These deferred share units will convert into shares of common stock upon settlement.
• Settlement occurs when Mr. Arduini ceases to be a director or at a future date he previously specified.
• The price per unit was $56.56, and the total value of the transaction was $33,759.99.
• Mr. Arduini now beneficially owns 56,788.276 shares of common stock, including deferred compensation and reinvested dividends.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed positively as it aligns director interests with shareholders. There are no negative implications.

Positives

• The acquisition of deferred share units by a director indicates confidence in the company's future performance.
• The deferred share units align the director's interests with those of the shareholders.

Future Outlook

The deferred share units will convert to common stock upon Mr. Arduini's departure as a director or at a previously specified date.

Industry Context

This is a routine filing related to director compensation and is common in the pharmaceutical industry.

Comparison to Industry Standards

• Deferred share unit grants are a common form of compensation for directors in publicly traded companies, including those in the pharmaceutical sector.
• Companies like Pfizer (PFE) and Merck (MRK) also use similar equity-based compensation plans for their directors.
• The vesting and settlement terms are typical, aligning director interests with long-term shareholder value.

Stakeholder Impact

• The acquisition of deferred share units by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term performance.

Key Dates

Keywords

Deferred Share Units, Director, Beneficial Ownership, Bristol-Myers Squibb, BMY, SEC Form 4, Stock Acquisition, Corporate Governance